2-deoxy-2-[18F]fluoro-d-mannose positron emission tomography imaging in atherosclerosis

Tahara, Nobuhiro; Mukherjee, Jogeshwar; Haas, Hans J. de; Petrov, Artiom; Tawakol, Ahmed; Haider, Nezam; Tahara, Atsuko; Constantinescu, Cristian; Zhou, Jun; Boersma, Hendrikus H.; Imaizumi, Tsutomu; Nakano, Masataka; Finn, Aloke V.; Fayad, Zahi A.; Virmani, Renu; Fuster, Valentín; Boscá, Lisardo; Narula, Jagat

doi:10.1038/nm.3437

Cited by 155 publications

(106 citation statements)

References 22 publications

Supporting

Mentioning

105

Contrasting

Order By: Relevance

“…Several noninvasive modalities has been evaluated, but, unfortunately, a method that can properly assess all the aspects of plaque and based on non invasive approach either at imaging or biochemical level, is still unavailable [11]. We found that increased circulating levels of ADAM17 substrates were associated to a significant higher rate of second cardiovascular events in a cohort of patients with established vascular atherosclerosis.…”

Section: Discussionmentioning

confidence: 80%

A score including ADAM17 substrates correlates to recurring cardiovascular event in subjects with atherosclerosis

et al. 2015

View full text Add to dashboard Cite

a b s t r a c tObjective: Atherosclerosis disease is a leading cause for mortality and morbidity. The narrowing/rupture of a vulnerable atherosclerotic plaque is accountable for acute cardiovascular events. However, despite of an intensive research, a reliable clinical method which may disclose a vulnerable patient is still unavailable.Approach and results: We tested the association of ADAM17 (A Disintegrin and Metallo Protease Domain 17) circulating substrates (sICAM-1, sVCAM-1, sIL6R and sTNFR1) with a second major cardiovascular events [MACEs] (cardiovascular death, peripheral artery surgeries, non-fatal myocardial infarction and non-fatal stroke) in 298 patients belonging to the Vascular Diabetes (AVD) study. To evaluate ADAM17 activity we create ADAM17 score through a RECPAM model. Finally we tested the discrimination ability and the reclassification of clinical models. At follow-up (mean 47 months, range 1e118 months), 55 MACEs occurred (14 nonfatal MI, 14 nonfatal strokes, 17 peripheral artery procedures and 10 cardiovascular deaths) (incidence ¼ 7.8% person-years). An increased risk for incident events was observed among the high ADAM17 score individuals both in univariable (HR 19.20, 95% CI 15.82e63.36, p < 0.001) and multivariable analysis (HR 3.42, 95% CI 1.55 e7.54, p < 0.001). Finally we found that ADAM17 score significantly increases the prediction accuracy of the Framingham Recurring-Coronary-Heart-Disease-Score, with a significant improvement in discrimination (integrated discrimination improvement ¼ 9%, p ¼ 0.012) and correctly reclassifying 10% of events and 41% of non-events resulting in a cNRI ¼ 0.51 (p ¼ 0.005). Conclusion: We demonstrated a positive role of ADAM17 activity to predicting CV events. We think that an approach that targets strategies beyond classic cardiovascular risk factors control is necessary in individuals with an established vascular atherosclerosis.

show abstract

Section: Discussionmentioning

confidence: 80%

A score including ADAM17 substrates correlates to recurring cardiovascular event in subjects with atherosclerosis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Several other PET tracers have been tested for use in atherosclerosis imaging, which might offer more specific markers of inflammation than 18 F-FDG or provide better methods for coronary artery imaging owing to inherently low myocardial tracer activity. These include 18 F-fluorodeoxymannose, the somatostatin receptor subtype-2 PET ligand 68 Ga-DOTATATE, 11 F-fluorocholine, and transient receptor protein receptor tracers, including 11 C-PK11195 [128][129][130][131]. Aside from inflammation, several other pathogenic mechanisms of atherosclerosis can be imaged using PET, including microcalcification, hypoxia, neo-angiogenesis, hematopoiesis, and HDL accumulation [126,[132][133][134][135].…”

Section: Positron Emission Tomographymentioning

confidence: 99%

Invasive or non-invasive imaging for detecting high-risk coronary lesions?

Patel

Tarkin

Serruys

et al. 2017

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Introduction: Advances in our understanding about atherosclerotic evolution have enabled us to identify specific plaque characteristics that are associated with coronary plaque vulnerability and cardiovascular events. With constant improvements in signal and image processing an arsenal of invasive and non-invasive imaging modalities have been developed that are capable of identifying these features allowing in vivo assessment of plaque vulnerability. Areas covered: This review article presents the available and emerging imaging modalities introduced to assess plaque morphology and biology, describes the evidence from the first large scale studies that evaluated the efficacy of invasive and non-invasive imaging in detecting lesions that are likely to progress and cause cardiovascular events and discusses the potential implications of the in vivo assessment of coronary artery pathology in the clinical setting. Expert commentary: Invasive imaging, with its high resolution, and in particular hybrid intravascular imaging appears as the ideal approach to study the mechanisms regulating atherosclerotic disease progression; whereas non-invasive imaging is expected to enable complete assessment of coronary tree pathology, detection of high-risk lesions, more accurate risk stratification and thus to allow a personalized treatment of vulnerable patients. ARTICLE HISTORY

show abstract

“…FDM also restricted binding of anti-mannose receptor antibody to macrophages by approximately 35%, so mannose receptors may be an additional target for imaging of plaque inflammation [337]. A novel system for dual-modality imaging of atherosclerotic plaques using the glucose probes [ polymorphisms are implicated as a cause in diabetic nephropathy and GLUT1 expression levels are altered in various tissues under diabetic conditions.…”

Section: Atherosclerosismentioning

confidence: 99%

Roles of facilitative glucose transporter GLUT1 in [18F]FDG positron emission tomography (PET) imaging of human diseases

Patching¹

2015

J Diagn Imaging Ther

View full text Add to dashboard Cite

The facilitative glucose transport protein GLUT1 has important roles in positron emission tomography (PET) imaging of human diseases. GLUT1 has widespread expression and catalyses the energyindependent facilitated diffusion of glucose down its concentration gradient across red blood cell membranes, blood-brain and blood-tissue barriers and membranes of some oragnelles. Import is usually the prevailing direction of transport for providing metabolic fuel, especially in proliferating cells. PET imaging using 2-deoxy-2-[ 18

show abstract

2-deoxy-2-[18F]fluoro-d-mannose positron emission tomography imaging in atherosclerosis

Cited by 155 publications

References 22 publications

A score including ADAM17 substrates correlates to recurring cardiovascular event in subjects with atherosclerosis

A score including ADAM17 substrates correlates to recurring cardiovascular event in subjects with atherosclerosis

Invasive or non-invasive imaging for detecting high-risk coronary lesions?

Roles of facilitative glucose transporter GLUT1 in [18F]FDG positron emission tomography (PET) imaging of human diseases

Contact Info

Product

Resources

About